𝔖 Bobbio Scriptorium
✦   LIBER   ✦

NF-κB and estrogen receptor α interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells

✍ Scribed by Nathalie Gionet; Deidre Jansson; Sylvie Mader; M.A. Christine Pratt


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
357 KB
Volume
107
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Estrogen receptor (ER)‐positive breast cancer cells have low levels of constitutive NF‐κB activity while ER negative (−) cells and hormone‐independent cells have relatively high constitutive levels of NF‐κB activity. In this study, we have examined the aspects of mutual repression between the ERα and NF‐κB proteins in ER+ and ER− hormone‐independent cells. Ectopic expression of the ERα reduced cell numbers in ER+ and ER− breast cancer cell lines while NF‐κB‐binding activity and the expression of several NF‐κB‐regulated proteins were reduced in ER− cells. ER overexpression in ER+/E2‐independent LCC1 cells only weakly inhibited the predominant p50 NF‐κB. GST‐ERα fusion protein pull downs and in vivo co‐immunoprecipitations of NF‐κB:ERα complexes showed that the ERα interacts with p50 and p65 in vitro and in vivo. Inhibition of NF‐κB increased the expression of diverse E2‐regulated proteins. p50 differentially associated directly with the ER:ERE complex in LCC1 and MCF‐7 cells by supershift analysis while p65 antibody reduced ERα:ERE complexes in the absence of a supershift. ChIP analysis demonstrated that NF‐κB proteins are present on an endogenous ERE. Together these results demonstrate that the ER and NF‐κB undergo mutual repression, which may explain, in part, why expression of the ERα in ER− cells does not confer growth signaling. Secondly, the acquisition of E2‐independence in ER+ cells is associated with predominantly p50:p50 NF‐κB, which may reflect alterations in the ER in these cells. Since the p50 homodimer is less sensitive to the presence of the ER, this may allow for the activation of both pathways in the same cell. J. Cell. Biochem. 107: 448–459, 2009. © 2009 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Steroid hormone receptors and coregulato
✍ Nanna Sarvilinna; Heli Eronen; Susanna Miettinen; Annika Vienonen; Timo Ylikomi 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 281 KB

## Abstract Resistance to hormonal therapy is often a problem in the treatment of breast cancer patients. It has been suggested that resistance could be explained by altered nuclear hormone receptor or coregulator levels or inappropriately increased agonist activity of selective estrogen receptor m

Targeting the NF-κB pathway in estrogen
✍ Noel R. Monks; Arthur B. Pardee 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

Cancer cells in order to survive are often mutated to block apoptosis. One chemotherapeutic option is the re-establishment of apoptosis. An example of such a therapy is the PKC inhibitor Go ¨6976, which activates apoptosis and shrinks in vivo tumors in estrogen receptor-negative breast cancers. We p

Estrogen-induced interaction between KLF
✍ Peng Guo; Xue-Yuan Dong; Ke-Wen Zhao; Xiaodong Sun; Qunna Li; Jin-Tang Dong 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 368 KB

## Abstract Kruppel‐like factor 5 (KLF5) is implicated in human breast cancer by frequent genomic deletion and expressional deregulation, but the molecular mechanisms by which KLF5 affects breast tumorigenesis are still unknown. This study was conducted to examine whether and how KLF5 affects the f

Differential expression of estrogen rece
✍ Lydia G. Marquez-Bravo; John F. Gierthy 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB

## Abstract Estrogens play a key role in the development and evolution of breast cancer tumors. Estrogen receptor alpha (ERα) mediates many of the biological activities of estrogens, and its expression is associated with low invasiveness and good prognosis. Recent epidemiological reports suggest th